Author:
Gallant Kat,Hayashi Kanna,Choi JinCheol,Milloy M-J,Kerr Thomas
Abstract
Abstract
Background
Retention in substance use treatment is essential to treatment success. While programmatic factors are known to influence retention, less is known about the role of involuntary discharges from drug or alcohol treatment programs. Therefore, we sought to identify the prevalence of and factors associated with involuntary discharge due to ongoing substance use.
Methods
Data were derived from two community-recruited prospective cohort studies of people who use drugs in Vancouver, Canada. Generalized estimating equation (GEE) analyses were used to identify variables associated with involuntary discharge from treatment programs due to ongoing substance use.
Results
Between June 2017 and March 2020, 1487 participants who accessed substance use treatment and completed at least one study interview were included in this study. Involuntary discharge from a treatment program due to ongoing substance use was reported by 41 (2.8%) participants throughout the study, with 23 instances reported at baseline and another 18 reported during study follow-up. In a multivariable GEE analysis, involuntary discharge was positively associated with homelessness (Adjusted Odds Ratio [AOR] = 3.22, 95% Confidence Interval [95% CI]: 1.59–6.52), daily injection drug use (AOR = 1.87, 95% CI 1.06–3.32) and recent overdose (AOR = 2.50, 95% CI 1.38–4.53), and negatively associated with age (AOR = 0.93, 95% CI 0.90–0.96). In sub-analyses, participants have most commonly been discharged from in-patient treatment centres (52.2%), recovery houses (28.3%) and detox programs (10.9%), and for using heroin (45.5%) and/or crystal methamphetamine (36.4%).
Conclusions
While involuntary discharge was a relatively rare occurrence, those who were discharged due to active substance use possessed several markers of risk, including high-intensity injection drug use, homelessness, and recent non-fatal overdose. Our findings highlight the need for increased flexibility within treatment programs to account for those who re-initiate or continue to use substances during treatment.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Federal provincial and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and stimulant-related Harms in Canada. Public Health Agency of Canada; December 2022. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/
2. Canadian Mental Health Association. Harm Reduction. 2022(September 19, 2022). https://ontario.cmha.ca/harm-reduction/
3. Marshall BDLP, Milloy MJM, Wood EP, Montaner JSGP, Kerr TP. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet (British Edition). 2011;377(9775):1429–37. https://doi.org/10.1016/S0140-6736(10)62353-7
4. Werb D, Kerr T, Buxton J, et al. Patterns of injection drug use cessation during an expansion of syringe exchange services in a Canadian setting. Drug Alcohol Depend Oct. 2013;1(3):535–40. https://doi.org/10.1016/j.drugalcdep.2013.03.024
5. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy Jan. 2014;25(1):34–52. https://doi.org/10.1016/j.drugpo.2013.07.001